Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548622 | PMC |
| http://dx.doi.org/10.1007/978-1-61779-328-8_32 | DOI Listing |
Publication Analysis
Top Keywords
neurodegenerative diseases
12
histone deacetylase
8
therapeutics neurodegenerative
8
gene expression
8
hdac inhibitors
8
evaluation histone
4
deacetylase inhibitors
4
inhibitors therapeutics
4
diseases neurodegenerative
4
diseases associated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!